Visen Pharmaceuticals   Report issue

For profit Phase 3
Founded: Shanghai China (2018)
Status: No NME R&D (2018)

Organization Overview

First Clinical Trial
2019
NCT04326374
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Visen Pharmaceuticals (Shanghai) Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

parathyroid hormone (Natpara) (1 trial)

somatropin (protropin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dwarfism, Pituitary (Phase 3)

Endocrine System Diseases (Phase 3)

Pituitary Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2